The departments of Health and Human Services and Defense have agreed to purchase the first 300,000 doses of the investigational antibody drug bamlanivimab, also known as LY-CoV555, which state and territorial health departments will distribute to health care facilities for use in COVID-19 outpatients if the Food and Drug Administration authorizes the drug.

Under the $375 million agreement with drug maker Eli Lilly and Company, the federal government also can purchase up to 650,000 additional doses of the intravenous infusion drug, which is currently in phase 3 clinical trials.

Related News Articles

Headline
The Centers for Disease Control and Prevention today announced shorter quarantine options based on local circumstances and resources, for people exposed to the…
Headline
The AHA today launched a new periodic report to convey to congressional staff hospitals’ and health systems’ desperate need for a new COVID-19 relief package…
Headline
Reps. Bradley Schneider, D-Ill., and David McKinley, R-W.Va., today introduced the Medicare Sequester COVID Moratorium Act, AHA-supported legislation that…
Headline
An independent advisory group for the Centers for Disease Control and Prevention yesterday recommended health care personnel and long-term care facility…
Headline
The Department of Health and Human Services should provide greater flexibility around health care staffing, provider resource allocation and accessibility to…
Headline
The Senate Homeland Security and Governmental Affairs Committee today held a hearing on defending communities from cyber threats during the COVID-19 pandemic…